Oliveira Raisa Arruda de, Santos Suellen Casado Dos, Lima Vera Lúcia de Menezes, Adami Luana Nayara Gallego
Embriológica, Pós-graduação, São Paulo, Brazil.
Universidade Federal de Pernambuco - UFPE, Recife, Brazil.
JBRA Assist Reprod. 2025 May 15;29(2):351-8. doi: 10.5935/1518-0557.20240109.
Selective Serotonin Reuptake Inhibitors are the most prescribed class of medications in cases of depression. This article discusses the main findings on their effects on male fertility, considering semen parameters and sperm function. This systematic review of the literature delves into the adverse effects of the main SSRIs on male fertility. The software package PRISMA was used to organize the search using keywords related to the research question. The search yielded a total of 125 studies. After the abstracts were read, 18 articles were selected for further analysis. The review ultimately included ten articles about the adverse effects of this class of antidepressants on male fertility, which included decreases in serum testosterone levels, reduced sperm production, decreased sperm reserves in the epididymis, and increased sperm transit time in the tail of the epididymis. The articles included in this review indicated that this class of antidepressants may have adverse effects on male fertility. However, a randomized clinical trial is needed to evaluate the mechanisms of spermatogenic failure and the underlying causes of these effects.
选择性5-羟色胺再摄取抑制剂是治疗抑郁症时处方量最多的一类药物。本文讨论了其对男性生育能力影响的主要研究结果,涉及精液参数和精子功能。对文献的这一系统综述深入探讨了主要选择性5-羟色胺再摄取抑制剂对男性生育能力的不良影响。使用PRISMA软件包,通过与研究问题相关的关键词进行检索。检索共得到125项研究。阅读摘要后,选择了18篇文章进行进一步分析。该综述最终纳入了10篇关于这类抗抑郁药对男性生育能力不良影响的文章,这些影响包括血清睾酮水平降低、精子生成减少、附睾中精子储备减少以及附睾尾部精子运输时间增加。本综述纳入的文章表明,这类抗抑郁药可能对男性生育能力有不良影响。然而,需要进行一项随机临床试验来评估生精失败的机制以及这些影响的潜在原因。
JBRA Assist Reprod. 2025-5-15
Cochrane Database Syst Rev. 2014-12-3
Cochrane Database Syst Rev. 2021-5-24
Cochrane Database Syst Rev. 2012-11-14
Cochrane Database Syst Rev. 2025-1-30
Cochrane Database Syst Rev. 2018-1-22
Cochrane Database Syst Rev. 2023-11-28
Cochrane Database Syst Rev. 2014-1-8
Cochrane Database Syst Rev. 2025-3-10
Front Pharmacol. 2022-9-14
Neurol Int. 2021-8-5
Front Endocrinol (Lausanne). 2021
Lancet. 2021-1-23
Neuropsychiatr Dis Treat. 2020-4-20